|
1.
|
Olson MT, Kickler TS, Lawson JA, McLean RC, Jani J, Fitzgerald GA, Rade JJ. Effect of assay specificity on the association of urine 11-dehydro thromboxane B(2) determination with cardiovascular risk. J Thromb Haemost. 2012 Dec; 10(12):2462-9.
|
|
|
|
|
2.
|
FitzGerald G, Boonen S, Compston JE, Pfeilschifter J, LaCroix AZ, Hosmer DW, Hooven FH, Gehlbach SH. Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2012 Sep; 27(9):1907-15.
|
|
|
|
|
3.
|
Park KL, Budaj A, Goldberg RJ, Anderson FA, Agnelli G, Kennelly BM, Gurfinkel EP, Fitzgerald G, Gore JM. Risk-Prediction Model for Ischemic Stroke in Patients Hospitalized With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2012 Sep 1; 110(5):628-35.
|
|
|
|
|
4.
|
Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012 Jun; 91(6):986-93.
|
|
|
|
|
5.
|
Barringhaus KG, Park KL, McManus DD, Steg PG, Montalescot G, Van de Werf F, López-Sendón J, FitzGerald G, Gore JM. Outcomes from patients with Multi-Vessel disease following primary PCI: staged PCI imparts very low mortality. Catheter Cardiovasc Interv. 2011 Apr 1; 77(5):617-22.
|
|
|
|
|
6.
|
Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep; 140(3):706-14.
|
|
|
|
|
7.
|
Daham K, Song WL, Lawson JA, Kupczyk M, Gülich A, Dahlén SE, FitzGerald GA, Dahlén B. Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy. 2011 Jan; 41(1):36-45.
|
|
|
|
|
8.
|
Waddell J, Johnson K, Hein W, Raabe J, FitzGerald G, Turibio F. Orthopaedic practice in total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):5-13.
|
|
|
|
|
9.
|
Friedman RJ, Gallus A, Gil-Garay E, FitzGerald G, Cushner F. Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):14-21.
|
|
|
|
|
10.
|
Cushner F, Agnelli G, FitzGerald G, Warwick D. Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):22-8.
|
|
|
|
|
11.
|
Warwick D, Agnelli G, Cushner F, Friedman RJ, FitzGerald G, Gallus A, GLORY Publication Committee . Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):29-31.
|
|
|
|
|
12.
|
Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011 Jan; 139(1):69-79.
|
|
|
|
|
13.
|
López-Sendón J, Gurfinkel EP, Lopez de Sa E, Agnelli G, Gore JM, Steg PG, Eagle KA, Cantador JR, Fitzgerald G, Granger CB. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010 Jun; 31(12):1449-56.
|
|
|
|
|
14.
|
Spencer FA, Montalescot G, Fox KA, Goodman SG, Granger CB, Goldberg RJ, Oliveira GB, Anderson FA, Eagle KA, Fitzgerald G, Gore JM. Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. Eur Heart J. 2010 Jun; 31(11):1328-36.
|
|
|
|
|
15.
|
Montalescot G, Brieger D, Eagle KA, Anderson FA, FitzGerald G, Lee MS, Steg PG, Avezum A, Goodman SG, Gore JM. Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J. 2009 Oct; 30(19):2308-17.
|
|
|
|
|
16.
|
Ruisi CP, Goldberg RJ, Kennelly BM, Goodman SG, Lopez-Sendon J, Granger CB, Avezum A, Eagle KA, FitzGerald G, Gore JM. Pulmonary artery catheterization in patients with acute coronary syndromes. Am Heart J. 2009 Aug; 158(2):170-6.
|
|
|
|
|
17.
|
Yu Y, Ricciotti E, Grosser T, Fitzgerald GA. The translational therapeutics of prostaglandin inhibition in atherothrombosis. J Thromb Haemost. 2009 Jul; 7 Suppl 1:222-6.
|
|
|
|
|
18.
|
Grad E, Golomb M, Koroukhov N, Lawson JA, Lotan C, Fitzgerald GA, Danenberg HD. Aspirin reduces the prothrombotic activity of C-reactive protein. J Thromb Haemost. 2009 Aug; 7(8):1393-400.
|
|
|
|
|
19.
|
Pieper KS, Gore JM, FitzGerald G, Granger CB, Goldberg RJ, Steg G, Eagle KA, Anderson FA, Budaj A, Fox KA. Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. Am Heart J. 2009 Jun; 157(6):1097-105.
|
|
|
|
|
20.
|
Yan AT, Steg PG, Fitzgerald G, Feldman LJ, Eagle KA, Gore JM, Anderson FA, López-Sendón J, Gurfinkel EP, Brieger D, Goodman SG. Recurrent ischemia across the spectrum of acute coronary syndromes: prevalence and prognostic significance of (re-)infarction and ST-segment changes in a large contemporary registry. Int J Cardiol. 2010 Nov 5; 145(1):15-20.
|
|
|
|
|
21.
|
Steg PG, FitzGerald G, Fox KA. Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough. Am J Med. 2009 Feb; 122(2):107-8.
|
|
|
|
|
22.
|
Medi C, Montalescot G, Budaj A, Fox KA, López-Sendón J, FitzGerald G, Brieger DB. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv. 2009 Jan; 2(1):26-33.
|
|
|
|
|
23.
|
Gore JM, Spencer FA, Gurfinkel EP, López-Sendón J, Steg PG, Granger CB, FitzGerald G, Agnelli G. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009 Jan 15; 103(2):175-80.
|
|
|
|
|
24.
|
Steg PG, Kerner A, Van de Werf F, López-Sendón J, Gore JM, Fitzgerald G, Feldman LJ, Anderson FA, Avezum A. Impact of in-hospital revascularization on survival in patients with non-ST-elevation acute coronary syndrome and congestive heart failure. Circulation. 2008 Sep 9; 118(11):1163-71.
|
|
|
|
|
25.
|
Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008 Jan; 24(1):87-97.
|
|
|
|
|
26.
|
Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KA. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007 Dec 11; 116(24):2793-801.
|
|
|
|
|
27.
|
Spencer FA, Goldberg RJ, Gore JM, Fox KA, Avezum A, Agnelli G, Kritharides L, Anderson FA, Goodman SG, FitzGerald G, Allegrone J, Brieger D. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl. Am J Cardiol. 2007 Sep 15; 100(6):913-8.
|
|
|
|
|
28.
|
Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007 Sep; 132(3):936-45.
|
|
|
|
|
29.
|
Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, Budaj A, Avezum A, Allegrone J, FitzGerald G, Steg PG. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007 Jul 1; 100(1):1-6.
|
|
|
|
|
30.
|
Eslami MH, Zayaruzny M, Fitzgerald GA. The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia. J Vasc Surg. 2007 Jan; 45(1):55-9.
|
|
|
|
|
31.
|
Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005 Mar 15; 38(6):698-710.
|
|
|
|
|
32.
|
Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, Basu S, Fitzgerald GA, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, Rokach J, Shigenaga MK, Sun J, Walter PB, Tomer KB, Barrett JC, Mason RP. Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med. 2005 Mar 15; 38(6):711-8.
|
|
|
|
|
33.
|
Regan CL, Levine RJ, Baird DD, Ewell MG, Martz KL, Sibai BM, Rokach J, Lawson JA, Fitzgerald GA. No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol. 2001 Sep; 185(3):572-8.
|
|
|
|
|
34.
|
Al-Abed Y, VanPatten S, Li H, Lawson JA, FitzGerald GA, Manogue KR, Bucala R. Characterization of a novel hemoglobin-glutathione adduct that is elevated in diabetic patients. Mol Med. 2001 Sep; 7(9):619-23.
|
|
|
|
|
35.
|
Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab. 2001 Aug; 12(6):243-7.
|
|
|
|
|
36.
|
Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. Am J Cardiol. 2001 Aug 1; 88(3):236-42.
|
|
|
|
|
37.
|
Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, Murphy S, FitzGerald GA. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood. 2001 May 15; 97(10):3093-9.
|
|
|
|
|
38.
|
Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA. 2001 Mar 7; 285(9):1178-82.
|
|
|
|
|
39.
|
Praticò D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3358-63.
|
|
|
|
|
40.
|
Praticò D, Tangirala RK, Hörkkö S, Witztum JL, Palinski W, FitzGerald GA. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. Blood. 2001 Jan 15; 97(2):459-64.
|
|
|
|
|
41.
|
Weinstein EA, Li H, Lawson JA, Rokach J, FitzGerald GA, Axelsen PH. Prothrombinase acceleration by oxidatively damaged phospholipids. J Biol Chem. 2000 Jul 28; 275(30):22925-30.
|
|
|
|
|
42.
|
McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, FitzGerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest. 2000 May; 105(10):1473-82.
|
|
|
|
|
43.
|
Burke A, Lawson JA, Meagher EA, Rokach J, FitzGerald GA. Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid. J Biol Chem. 2000 Jan 28; 275(4):2499-504.
|
|
|
|
|
44.
|
Li H, Lawson JA, Reilly M, Adiyaman M, Hwang SW, Rokach J, FitzGerald GA. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A. 1999 Nov 9; 96(23):13381-6.
|
|
|
|
|
45.
|
Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, FitzGerald GA. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest. 1999 Sep; 104(6):805-13.
|
|
|
|
|
46.
|
Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999 Aug 27; 274(35):24441-4.
|
|
|
|
|
47.
|
Al-Abed Y, Mitsuhashi T, Li H, Lawson JA, FitzGerald GA, Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R. Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. Proc Natl Acad Sci U S A. 1999 Mar 2; 96(5):2385-90.
|
|
|
|
|
48.
|
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999 Jan 5; 96(1):272-7.
|
|
|
|
|
49.
|
Biener L, Fitzgerald G. Smoky bars and restaurants: who avoids them and why? J Public Health Manag Pract. 1999 Jan; 5(1):74-8.
|
|
|
|
|
50.
|
Praticò D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998 Dec; 12(15):1777-83.
|
|
|
|
|
51.
|
Reilly MP, Praticò D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998 Dec 22-29; 98(25):2822-8.
|
|
|
|
|
52.
|
Lawson JA, Li H, Rokach J, Adiyaman M, Hwang SW, Khanapure SP, FitzGerald GA. Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine. J Biol Chem. 1998 Nov 6; 273(45):29295-301.
|
|
|
|
|
53.
|
Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation. 1998 Oct 20; 98(16):1610-5.
|
|
|
|
|
54.
|
Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem. 1998 Aug 28; 273(35):22442-52.
|
|
|
|
|
55.
|
Adiyaman M, Lawson JA, Khanapure SP, FitzGerald GA, Rokach J. Total synthesis of 17,17,18,18-d4-iPF2alpha-VI and quantification of iPF2alpha-VI in human urine by gas chromatography/mass spectrometry. Anal Biochem. 1998 Aug 15; 262(1):45-56.
|
|
|
|
|
56.
|
Praticò D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP, Iuliano L, Rokach J, FitzGerald GA. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7):3449-54.
|
|
|
|
|
57.
|
Reilly MP, Lawson JA, FitzGerald GA. Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. J Nutr. 1998 Feb; 128(2 Suppl):434S-438S.
|
|
|
|
|
58.
|
Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. The isoprostanes: a perspective. Prostaglandins. 1997 Dec; 54(6):823-51.
|
|
|
|
|
59.
|
Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. Nomenclature of isoprostanes: a proposal. Prostaglandins. 1997 Dec; 54(6):853-73.
|
|
|
|
|
60.
|
Reilly MP, Delanty N, Roy L, Rokach J, Callaghan PO, Crean P, Lawson JA, FitzGerald GA. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 1997 Nov 18; 96(10):3314-20.
|
|
|
|
|
61.
|
Iuliano L, Praticò D, Ferro D, Pittoni V, Valesini G, Lawson J, FitzGerald GA, Violi F. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood. 1997 Nov 15; 90(10):3931-5.
|
|
|
|
|
62.
|
Kunapuli P, Lawson JA, Rokach J, FitzGerald GA. Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem. 1997 Oct 24; 272(43):27147-54.
|
|
|
|
|
63.
|
Praticò D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, Maclouf J, Violi F, FitzGerald GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997 Oct 15; 100(8):2028-34.
|
|
|
|
|
64.
|
FitzGerald GA, Tigges J, Barry P, Lawson JA. Markers of platelet activation and oxidant stress in atherothrombotic disease. Thromb Haemost. 1997 Jul; 78(1):280-4.
|
|
|
|
|
65.
|
Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation. 1997 Jun 3; 95(11):2492-9.
|
|
|
|
|
66.
|
Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997 May 1; 99(9):2118-27.
|
|
|
|
|
67.
|
Praticò D, Reilly M, Lawson JA, FitzGerald GA. Novel indices of oxidant stress in cardiovascular disease: specific analysis of F2-isoprostanes. Agents Actions Suppl. 1997; 48:25-41.
|
|
|
|
|
68.
|
Pratico D, O'Mahony D, Lawson J, Kinsella T, Fitzgerald GA. Cellular activation by thromboxane A2 and 8-EPI-PGF2 alpha. Adv Exp Med Biol. 1997; 400A:229-33.
|
|
|
|
|
69.
|
Vezza R, Habib A, Li H, Lawson JA, FitzGerald GA. Regulation of cyclooxygenases by protein kinase C. Evidence against the importance of direct enzyme phosphorylation. J Biol Chem. 1996 Nov 22; 271(47):30028-33.
|
|
|
|
|
70.
|
Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996 Jul 1; 94(1):19-25.
|
|
|
|
|
71.
|
Delanty N, Reilly M, Pratico D, FitzGerald DJ, Lawson JA, FitzGerald GA. 8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol. 1996 Jul; 42(1):15-9.
|
|
|
|
|
72.
|
Wang Z, Ciabattoni G, Créminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995 Oct; 275(1):94-100.
|
|
|
|
|
73.
|
Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem. 1995 Apr 28; 270(17):9800-8.
|
|
|
|
|
74.
|
Pratico D, Lawson JA, Fitzgerald GA. Cyclooxygenase dependent formation of 8-iso-prostaglandin F2 alpha by human platelets. Adv Prostaglandin Thromboxane Leukot Res. 1995; 23:229-31.
|
|
|
|
|
75.
|
Catella F, Reilly MP, Delanty N, Lawson JA, Moran N, Meagher E, FitzGerald GA. Physiological formation of 8-epi-PGF2 alpha in vivo is not affected by cyclooxygenase inhibition. Adv Prostaglandin Thromboxane Leukot Res. 1995; 23:233-6.
|
|
|
|
|
76.
|
Pratico D, Reilly M, Lawson J, Delanty N, FitzGerald GA. Formation of 8-iso-prostaglandin F2 alpha by human platelets. Agents Actions Suppl. 1995; 45:27-31.
|
|
|
|
|
77.
|
Pratico D, Lawson JA, Fitzgerald GA. Cyclooxygenase-dependent formation of the isoprostane 8-epi prostaglandin F2 alpha. Ann N Y Acad Sci. 1994 Nov 15; 744:139-45.
|
|
|
|
|
78.
|
Kinsella BT, O'Mahony D, Lawson JA, Pratico D, Fitzgerald GA. Cellular activation of thromboxane receptors. Ann N Y Acad Sci. 1994 Apr 18; 714:270-8.
|
|
|
|
|
79.
|
Catella F, Lawson J, Braden G, Fitzgerald DJ, Shipp E, FitzGerald GA. Biosynthesis of P450 products of arachidonic acid in humans: increased formation in cardiovascular disease. Adv Prostaglandin Thromboxane Leukot Res. 1991; 21A:193-6.
|
|
|
|
|
80.
|
Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A. 1990 Aug; 87(15):5893-7.
|
|
|
|
|
81.
|
Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res. 1988 May 1; 50(3):377-86.
|
|
|
|
|
82.
|
FitzGerald GA, Fitzgerald DJ, Lawson JA, Murray R. Thromboxane biosynthesis and antagonism in humans. Adv Prostaglandin Thromboxane Leukot Res. 1987; 17A:199-203.
|
|
|
|
|
83.
|
Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Analysis of multiple thromboxane metabolites in plasma and urine. Adv Prostaglandin Thromboxane Leukot Res. 1987; 17B:611-4.
|
|
|
|
|
84.
|
Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A. 1986 Aug; 83(16):5861-5.
|
|
|
|
|
85.
|
Lawson JA, Patrono C, Ciabattoni G, Fitzgerald GA. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal Biochem. 1986 May 15; 155(1):198-205.
|
|
|
|
|
86.
|
Lawson JA, Brash AR, Doran J, FitzGerald GA. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry. Anal Biochem. 1985 Nov 1; 150(2):463-70.
|
|
|
|
|
87.
|
FitzGerald GA, Lawson J, Blair IA, Brash AR. Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry. Adv Prostaglandin Thromboxane Leukot Res. 1985; 15:87-90.
|
|
|
|
|
88.
|
Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther. 1983 Jul; 226(1):78-87.
|
|
|
|
|
89.
|
FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar; 71(3):676-88.
|
|
|
|
|
90.
|
Brash AR, Jackson EK, Lawson JA, Branch RA, Oates JA, FitzGerald GA. Quantitative aspects of prostacyclin metabolism in humans. Adv Prostaglandin Thromboxane Leukot Res. 1983; 11:119-22.
|
|
|
|
|
91.
|
FitzGerald GA, Maas RL, Lawson JA, Oates JA, Roberts LJ, Brash AR. Aspirin inhibits endogenous prostacyclin and thromboxane biosynthesis in man. Adv Prostaglandin Thromboxane Leukot Res. 1983; 11:265-6.
|
|
|
|
